Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
1.460
0.00 (0.00%)
Sep 4, 2025, 4:00 PM - Market closed

Humacyte Statistics

Total Valuation

Humacyte has a market cap or net worth of $231.22 million. The enterprise value is $277.16 million.

Market Cap231.22M
Enterprise Value 277.16M

Important Dates

The last earnings date was Monday, August 11, 2025, before market open.

Earnings Date Aug 11, 2025
Ex-Dividend Date n/a

Share Statistics

Humacyte has 158.37 million shares outstanding. The number of shares has increased by 22.81% in one year.

Current Share Class 158.37M
Shares Outstanding 158.37M
Shares Change (YoY) +22.81%
Shares Change (QoQ) +17.85%
Owned by Insiders (%) 7.25%
Owned by Institutions (%) 36.94%
Float 125.19M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 238.10
Forward PS 16.25
PB Ratio 56.33
P/TBV Ratio 57.06
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 338.82
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.45, with a Debt / Equity ratio of 20.72.

Current Ratio 2.45
Quick Ratio 1.82
Debt / Equity 20.72
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -10.60

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -50.18%
Return on Invested Capital (ROIC) -100.22%
Return on Capital Employed (ROCE) -94.50%
Revenue Per Employee $3,718
Profits Per Employee -$266,945
Employee Count220
Asset Turnover 0.01
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -73.62% in the last 52 weeks. The beta is 1.87, so Humacyte's price volatility has been higher than the market average.

Beta (5Y) 1.87
52-Week Price Change -73.62%
50-Day Moving Average 2.10
200-Day Moving Average 2.92
Relative Strength Index (RSI) 33.44
Average Volume (20 Days) 5,710,960

Short Selling Information

The latest short interest is 34.25 million, so 21.63% of the outstanding shares have been sold short.

Short Interest 34.25M
Short Previous Month 31.87M
Short % of Shares Out 21.63%
Short % of Float 27.36%
Short Ratio (days to cover) 6.17

Income Statement

In the last 12 months, Humacyte had revenue of $818,000 and -$58.73 million in losses. Loss per share was -$0.44.

Revenue818,000
Gross Profit -80.55M
Operating Income -111.23M
Pretax Income -105.70M
Net Income -58.73M
EBITDA -103.92M
EBIT -111.23M
Loss Per Share -$0.44
Full Income Statement

Balance Sheet

The company has $38.03 million in cash and $83.96 million in debt, giving a net cash position of -$45.93 million or -$0.29 per share.

Cash & Cash Equivalents 38.03M
Total Debt 83.96M
Net Cash -45.93M
Net Cash Per Share -$0.29
Equity (Book Value) 4.05M
Book Value Per Share 0.03
Working Capital 30.65M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$104.50 million and capital expenditures -$1.79 million, giving a free cash flow of -$106.29 million.

Operating Cash Flow -104.50M
Capital Expenditures -1.79M
Free Cash Flow -106.29M
FCF Per Share -$0.67
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin -13,598.04%
Pretax Margin -7,171.27%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Humacyte does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -22.81%
Shareholder Yield -22.81%
Earnings Yield -25.40%
FCF Yield -45.97%

Analyst Forecast

The average price target for Humacyte is $10.88, which is 645.21% higher than the current price. The consensus rating is "Strong Buy".

Price Target $10.88
Price Target Difference 645.21%
Analyst Consensus Strong Buy
Analyst Count 8
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Humacyte has an Altman Z-Score of -6.82. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -6.82
Piotroski F-Score n/a